[Skip to Navigation]
Sign In
Viewpoint
April 15, 2021

Evaluating Cancer Drugs in Patients With Central Nervous System Metastases

Author Affiliations
  • 1Office of Oncologic Diseases, US Food and Drug Administration, Silver Spring, Maryland
  • 2Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland
JAMA Oncol. 2021;7(8):1111-1112. doi:10.1001/jamaoncol.2021.0180

In early 2020, the US Food and Drug Administration (FDA) approved tucatinib, an oral tyrosine kinase inhibitor (TKI) of the protein ERBB2 (formerly HER2), in combination with trastuzumab and capecitabine for treatment of patients with locally advanced or metastatic breast cancer, including patients with brain metastases.1 The approval was based on HER2CLIMB (A Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Advanced HER2+ Breast Cancer),1,2 a randomized, double-blinded, placebo-controlled clinical trial that enrolled 612 patients and demonstrated statistically significant improvement in progression-free survival (PFS), overall survival (OS), and PFS in patients with brain metastases. Patients with active brain metastases have been historically excluded from clinical trials; however, HER2CLIMB enrolled patients with brain metastases, including those with progressing or untreated lesions.

Add or change institution
×